{"task_id": "c4618992ab78379a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 224/464)", "text": "ac tumor. Half life 2 3 days\nTesticular Cancer\n213\n\n--- Page 235 ---\nTumor\nbhCG\naFP\nNon seminoma\n\" in up to 85%\n\" in up to 80%\nSeminoma\n\" in 15 25%\nNormal\nPROGNOSTIC FACTORS\nvascular invasion is most\nimportant indicator for relapse in non seminoma\nMANAGEMENT\nNOTE: all cases should be discussed with an interdis\nciplinary team experienced in the management of\ntesticular cancer\nEARLY SEMINOMA\n\u0002\nSTAGE I\norchiectomy + one of adjuvant radia\ntion (paraaortic/paracaval LN, 3 4% relapse) or\nadjuvant carboplatin (1 2 cycles, 3 4% relapse)\nor surveillance (15 20% relapse (higher risk of\nrecurrence if >4 cm or rete testis involvement)\n\u0002\nSTAGE IIA\norchiectomy + radiation (paraaortic/\nipsilateral iliac LN, 6 year RFS 95%)\n\u0002\nSTAGE IIB\norchiectomy + one of radiation (para\naortic/ipsilateral iliac LN, 6 year RFS 89%) or che\nmotherapy (if radiation not given, BEP\u00033 or EP\u00034,\nwhere B=bleomycin, E=etoposide, P=cisplatin)\nEARLY NON SEMINOMA\n\u0002\nSTAGE I WITH\nNO\nVASCULAR\nINVASION (14 22%\nrelapse)\norchiectomy + one of surveillance\n(14 22% relapse) or chemotherapy (if surveil\nlance not chosen, BEP\u00032) or nerve sparing retro\nperitoneal [NSRP] LN dissection (if both surveil\nlance and chemotherapy not chosen). Surveillance\nis recommended\n\u0002\nSTAGE I WITH VASCULAR INVASION (48% relapse)\norchiectomy + one of chemotherapy (BEP\u00032,\n3% relapse) or surveillance (if chemotherapy not\ngiven, 48% relapse) or NSRP LN dissection (if\nboth surveillance and chemotherapy not chosen,\n10% relapse). Surveillance is recommended\n\u0002\nSTAGE IIA, MARKER NEGATIVE\norchiectomy + one of\n\u0002 NSRP LN dissection ! if pathologic stage IIA or\nIIB, BEP\u00032; if stage I, surveillance only, or surveil\nlance (follow up every 6 weeks) ! if regression,\nfollow up only; if no change, NSRP LN dissection or\nclose follow up; if progressive disease, BEP\u00033 or\nNSRP LN dissection\n\u0002\nSTAGE IIA,\nMARKER\nPOSITIVE\norchiectomy\n+\nBEP\u00033 + resection if residual tumor\n\u0002\nSTAGE IIB\norchiectomy + BEP\u00033 + resection if\nresidual tumor\nADVANCED SEMINOMA AND NON SEMINOMA\n(IIC, IIIA C)\n\u0002\nGOOD\nRISK\norchiectomy\n+\nchemotherapy\n(BEP\u00033 or EP\u00034)\n\u0002\nINTERMEDIATE/POOR\nRISK\norchiectomy + che\nmotherapy (BEP\u00034)\n\u0002\nRESIDUAL\nTUMOR\nPOST-CHEMOTHERAPY\nmarker\nnormalized (proceed to resection ! if necrosis\n(40%), differentiated teratoma (40%) or <10%\nviable tumors, follow up only; if >10% viable\ntumors,\nconsolidative\nchemotherapy\nwith\nVIP\u00032; if incomplete resection of viable tumor,\ntreat as marker increased), marker elevated but\nplateau (follow up 4 12 weeks ! treat as mar\nker normalized or marker increased depending\non trend), marker increased after short inter\nval (salvage chemotherapy with PEI\u00034, VIP\u00034,\nVeIP\u00034, TIP\u00034)\n\u0002\nNOTE\nB=bleomycin,\nE/V=etoposide\n(VP16),\nP=cisplatin, I=ifosfamide, Ve=vinblastine, T=taxol\nRELAPSED SEMINOMA\nif systemic relapse, con\nsider BEP\u00034. If locoregional relapse, consider BEP or\nradiotherapy. Salvage chemotherapy regimens after\nfirst line chemotherapy include PEI\u00034, VIP\u00034, or\nVeIP\u00034 or TIP\u00034\nRELAPSED NON SEMINOMA\nsalvage chemother\napy regimens after first line chemotherapy include\nPEI\u00034, VIP\u00034, or VeIP\u00034 or TIP\u00034. For late relapses,\npatients with negative tumor markers should have\nimmediate radical surgery. If unresectable disease,\nconsider salvage chemotherapy and then resection\nif possible. If unresectable disease and localized, con\nsider radiotherapy\nTREATMENT ISSUES\nGROWING TERATOMA SYNDROME\ndefined as\nenlargement of a residual mass post chemotherapy,\ndespite complete normalization of tumor marker sug\ngesting eradication of malignant population. Surgical\nresection is indicated for a growing teratoma as it\ndoes not respond to chemotherapy or radiation and\nmay transform into malignant tumors such as adeno\ncarcinoma or rhabdomyosarcoma\nRADICAL ORCHIECTOMY\nshould always be done\nprior to any further treatment, except for life threa\ntening metastatic disease in which chemotherapy\nshould be given first\nORGAN PRESERVING SURGERY\nshould be done\nat experienced centers only. Consider if synchronous\nbilateral testis tumors, metachronous contralateral\n(second) testis tumor, or tumor in a solitary testis\nand sufficient endocrine function\nFERTILITY\nISSUES\nconsider\ncryoconservation\nbefore orchiectomy and testicular sperm extrac\ntion if bilateral orchiectomy. Testosterone replace\nment should be given if bilateral orchiectomy.\nPatients planning to father children should have\nhormone and semen analysis for 1 to 3 year post\ntreatment\nMANAGEMENT (CONT\u2019D)\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\n214\nTesticular Cancer", "text_length": 4483, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 224/464)", "type": "chunk", "chunk_index": 223, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.554936", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.555703", "status": "complete", "chunks_added": 3}